Internal Server Error

AiCuris - About the company

AiCuris is an acquired company based in Wuppertal (Germany), founded in 2006. It operates as a Developer of antiviral and antibacterial therapeutics for infectious diseases. AiCuris has raised $74.8M in funding. The company has 300 active competitors, including 75 funded and 75 that have exited. Its top competitors include companies like Tonix Pharma, HOOKIPA Pharma and Ascletis Pharma.

Company Details

Developer of antiviral and antibacterial therapeutics for infectious diseases. The pipeline includes the development of AIC246 (Prevymis) for treating human cytomegalovirus (quinazoline-based inhibitor of the cytomegalovirus (CMV) terminase protein), AIC316 (phase II) for the treatment Herpes simplex, and AIC649 (Phase I) for Hepatitis B virus.
Social
X
Registered Address
Friedrich-Ebert-Straße 475 42117 Wuppertal
Key Metrics
Founded Year
2006
Location
Wuppertal, Germany
Stage
Acquired
Total Funding
$74.8M in 4 rounds
Ranked
Annual Revenue
€50M - €100M as on Dec 31, 2018
Employee Count
75 as on Sep 30, 2026
Similar Companies
Exit Details
Acquired by Asahi Kasei (Feb 26, 2026)

AiCuris's acquisition details

AiCuris got acquired by Asahi Kasei on Feb 26, 2026 at an acquisition amount of $*****.
Click here to take a look at AiCuris's acquisition in detail
Sign up to download AiCuris' company profile

AiCuris's funding and investors

AiCuris has raised a total funding of $74.8M over 4 rounds. Its first funding round was on Apr 14, 2010.

Here is the list of recent funding rounds of AiCuris:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Nov 01, 2017
2541507
Grant (prize money)
9692531
4359083
1980879
8897580
Jan 01, 2017
3935919
Grant (prize money)
1031827
3052611
2475383
4422276
Mar 01, 2015
2762165
Grant (prize money)
5706778
5106668
6143684
1176652
lockAccess funding benchmarks and valuations. Sign up today!

AiCuris' founders and board of directors

Founder? Claim Profile

AiCuris' employee count trend

AiCuris has 75 employees as of Sep 26. Here is AiCuris's employee count trend over the years:
Employee count trend for AiCuris
lockUncover AiCuris' growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

AiCuris's Competitors and alternates

Top competitors of AiCuris include Tonix Pharma, HOOKIPA Pharma and Ascletis Pharma. Here is the list of Top 10 competitors of AiCuris, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Tonix Pharma
Tonix Pharma
2007, New York City (United States), Public
Developer of next-generation medicines for CNS and immunological disorders
$4.45M
67/100
2nd
Logo for HOOKIPA Pharma
HOOKIPA Pharma
2011, Vienna (Austria), Public
Developer of immunotherapies for the treatment of infectious diseases and cancer
$134M
65/100
3rd
Logo for Ascletis Pharma
Ascletis Pharma
2011, Hangzhou (China), Public
Developer of small molecules for the treatment of multiple diseases
$255M
64/100
4th
Logo for Vaxart
Vaxart
2004, San Francisco (United States), Public
Developer of therapeutic solutions for treating multiple infectious diseases
$58M
64/100
5th
Logo for eradivir
eradivir
2020, West Lafayette (United States), Series A
Developer of immunotherapies for the treatment of infectious diseases
$20.4M
62/100
6th
Logo for VBI Vaccines
VBI Vaccines
2001, Cambridge (United States), Public
Developer of vaccines for the treatment of infectious diseases
$65.1M
61/100
7th
Logo for Ocugen
Ocugen
2013, Aurora (United States), Public
Developer of therapeutic solutions to treat various eye disorders
-
61/100
8th
Logo for SAB Biotherapeutics
SAB Biotherapeutics
2014, Sioux Falls (United States), Public
Developer of immunotherapeutics to treat infectious and autoimmune diseases
$49M
61/100
9th
Logo for Brii Biosciences
Brii Biosciences
2018, San Francisco (United States), Public
Developer of biologics to treat hepatitis B infection
$415M
60/100
10th
Logo for Leyden Labs
Leyden Labs
2020, Leiden (Netherlands), Series B
Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa
$303M
59/100
39th
Logo for AiCuris
AiCuris
2006, Wuppertal (Germany), Acquired
Developer of antiviral and antibacterial therapeutics for infectious diseases
$74.8M
-
51/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on AiCuris's competitors? Click here to see the top ones

AiCuris's Investments and acquisitions

AiCuris has made no investments or acquisitions yet.

Reports related to AiCuris

Here is the latest report on AiCuris's sector:

News related to AiCuris

lockFilter this list
Media has covered AiCuris for a total of 15 events in the last 1 year, 5 of them have been about company updates.
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about AiCuris

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford